Literature DB >> 29666020

Geographic Variation in the Treatment of U.S. Adult Heart Transplant Candidates.

William F Parker1, Allen S Anderson2, Donald Hedeker3, Elbert S Huang4, Edward R Garrity4, Mark Siegler4, Matthew M Churpek5.   

Abstract

BACKGROUND: The current U.S. priority ranking for heart candidates is based on treatment intensity, not objective markers of severity of illness. This system may encourage centers to overtreat candidates.
OBJECTIVES: This study sought to describe national variation in the intensity of treatment of adult heart transplantation candidates and identify center-level predictors of potential overtreatment.
METHODS: The registrations of all U.S. adult heart transplantation candidates from 2010 to 2015 were collected from the SRTR (Scientific Registry of Transplant Recipients). "Potential overtreatment" was defined as treatment of a candidate who did not meet American Heart Association cardiogenic shock criteria with either high-dose inotropes or an intra-aortic balloon pump. Multilevel logistic regression and propensity score models were used to adjust for candidate variability at each center. Center-level variables associated with potential overtreatment were identified.
RESULTS: From 2010 to 2015, 108 centers listed 12,762 adult candidates who were not in cardiogenic shock for heart transplantation. Of these, 1,471 (11.6%) were potentially overtreated with high-dose inotropes or intra-aortic balloon pumps. In the bottom quartile of centers, only 2.1% of candidates were potentially overtreated compared with 27.6% at top quartile centers, an interquartile difference of 25.5% (95% confidence interval: 21% to 30%). Adjusting for candidate differences did not significantly alter the interquartile difference. Local competition with 2 or more centers increased the odds of potential overtreatment by 50% (adjusted odds ratio: 1.50; 95% confidence interval: 1.07 to 2.11).
CONCLUSIONS: There is wide variation in the treatment practices of adult heart transplantation centers. Competition for transplantable donor hearts is associated with the potential overtreatment of hemodynamically stable candidates. Overtreatment may compromise the fair and efficient allocation of scarce deceased donor hearts.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ethics; heart transplantation; organ allocation

Mesh:

Year:  2018        PMID: 29666020      PMCID: PMC6019274          DOI: 10.1016/j.jacc.2018.02.030

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  Massachusetts cardiac surgery report card: implications of statistical methodology.

Authors:  David M Shahian; David F Torchiana; Richard J Shemin; James D Rawn; Sharon-Lise T Normand
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

2.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

3.  The relationship between two performance scales: New York Heart Association Classification and Karnofsky Performance Status Scale.

Authors:  Miriam J Johnson; J Martin Bland; Patricia M Davidson; Phillip J Newton; Stephen G Oxberry; Amy P Abernethy; David C Currow
Journal:  J Pain Symptom Manage       Date:  2013-07-30       Impact factor: 3.612

4.  The urgent priority for transplantation is to trim the waiting list.

Authors:  Lynne Warner Stevenson
Journal:  J Heart Lung Transplant       Date:  2013-09       Impact factor: 10.247

5.  Comparison of "risk-adjusted" hospital outcomes.

Authors:  David M Shahian; Sharon-Lise T Normand
Journal:  Circulation       Date:  2008-04-07       Impact factor: 29.690

6.  Survival benefit from transplantation in patients listed for heart transplantation in the United States.

Authors:  Tajinder P Singh; Carly E Milliren; Christopher S Almond; Dionne Graham
Journal:  J Am Coll Cardiol       Date:  2014-01-30       Impact factor: 24.094

7.  Inaccuracy of estimated resting oxygen uptake in the clinical setting.

Authors:  Nikhil Narang; Jennifer T Thibodeau; Benjamin D Levine; M Odette Gore; Colby R Ayers; Richard A Lange; Joaquin E Cigarroa; Aslan T Turer; James A de Lemos; Darren K McGuire
Journal:  Circulation       Date:  2013-09-27       Impact factor: 29.690

8.  Evaluating obstetrical residency programs using patient outcomes.

Authors:  David A Asch; Sean Nicholson; Sindhu Srinivas; Jeph Herrin; Andrew J Epstein
Journal:  JAMA       Date:  2009-09-23       Impact factor: 56.272

9.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

Authors:  M Packer; J R Carver; R J Rodeheffer; R J Ivanhoe; R DiBianco; S M Zeldis; G H Hendrix; W J Bommer; U Elkayam; M L Kukin
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

10.  Effect of the degree of tricuspid regurgitation on cardiac output measurements by thermodilution.

Authors:  Martin Balik; Jan Pachl; Jan Hendl; Balik Martin; Pachl Jan; Hendl Jan
Journal:  Intensive Care Med       Date:  2002-06-15       Impact factor: 17.440

View more
  9 in total

1.  Practice Changes at U.S. Transplant Centers After the New Adult Heart Allocation Policy.

Authors:  William F Parker; Kevin Chung; Allen S Anderson; Mark Siegler; Elbert S Huang; Matthew M Churpek
Journal:  J Am Coll Cardiol       Date:  2020-06-16       Impact factor: 24.094

Review 2.  Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology.

Authors:  Ravi B Patel; Muthiah Vaduganathan; Stephen J Greene; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-06-26       Impact factor: 15.534

3.  Epistemic Authority and Trust in Shared Decision Making About Organ Transplantation.

Authors:  William F Parker; Marshall H Chin
Journal:  AMA J Ethics       Date:  2020-05-01

4.  Reply: Does Overtreatment of Heart Transplantation Candidates Exist?

Authors:  William F Parker; Allen S Anderson; Elbert S Huang; Edward R Garrity; Matthew M Churpek
Journal:  J Am Coll Cardiol       Date:  2018-08-07       Impact factor: 24.094

5.  Association of Transplant Center With Survival Benefit Among Adults Undergoing Heart Transplant in the United States.

Authors:  William F Parker; Allen S Anderson; Robert D Gibbons; Edward R Garrity; Lainie F Ross; Elbert S Huang; Matthew M Churpek
Journal:  JAMA       Date:  2019-11-12       Impact factor: 56.272

6.  Between-center variation in high-priority listing status under the new heart allocation policy.

Authors:  Gege Ran; Kevin Chung; Allen S Anderson; Robert D Gibbons; Nikhil Narang; Matthew M Churpek; William F Parker
Journal:  Am J Transplant       Date:  2021-05-05       Impact factor: 8.086

7.  Center-level Utilization of Hepatitis C Virus-positive Donors for Orthotopic Heart Transplantation.

Authors:  Lauren V Huckaby; Laura M Seese; Robert Handzel; Yisi Wang; Gavin Hickey; Arman Kilic
Journal:  Transplantation       Date:  2021-12-01       Impact factor: 4.939

8.  Trends in the utilization of marginal donors for orthotopic heart transplantation.

Authors:  Lauren V Huckaby; Gavin Hickey; Ibrahim Sultan; Arman Kilic
Journal:  J Card Surg       Date:  2021-01-23       Impact factor: 1.778

9.  State-Level Variation in Waitlist Mortality and Transplant Outcomes Among Patients Listed for Heart Transplantation in the US From 2011 to 2016.

Authors:  Emmanuel Akintoye; Doosup Shin; Paulino Alvarez; Alexandros Briasoulis
Journal:  JAMA Netw Open       Date:  2020-12-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.